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Abstract: Benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) 
are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS due to 
BPH. Alpha-adrenergic receptor blockers remain one of the mainstays in the treatment of male 
LUTS and clinical BPH. They exhibit early onset of efficacy with regard to both symptoms 
and flow rate improvement, and this is clearly demonstrated in placebo-controlled trials with 
extensions out to five years. These agents have been shown to prevent symptomatic progression 
of the disease. The aim of this article is to offer a critical review of the current literature on 
silodosin, formerly known as KMD-3213, a novel alpha-blocker with unprecedented selectivity 
for α1A-adrenergic receptors, as compared with both α1B- and α1D -adrenoceptors, exceeding the 
selectivity of all currently used α1-blockers, and with clinically promising effects.
Keywords: silodosin, α1A- blockers, lower urinary tract symptoms, benign prostatic   hyperplasia, 
uroselectivity
Introduction
Benign prostatic hyperplasia (BPH) is a common problem among men after the age 
of 40 years. The prevalence of BPH increases from approximately 50% at 60 years to 
90% in men older than 85 years.1–3 BPH is the most important cause of lower urinary 
tract symptoms (LUTS) in males, and 50% of men with BPH complain of LUTS.2 Male 
LUTS can be classified into three categories, ie, voiding or obstructive (hesitancy, slow 
stream, intermittency, incomplete emptying), storage or irritative (frequency, urgency, 
nocturia, urge urinary incontinence), and postmicturition (postvoid dribbling).4 These 
conditions have a significant impact on overall quality of life.5
Histologically, BPH develops in the periurethral or transitional zone of the prostate 
through an increase in the stromal component of the gland, and, to a lesser degree, 
epithelial cells.1,6 This proliferation leads to urethral constriction. The pathogenesis of 
BPH is still not well understood, but involves several complicated pathways, including 
inflammation, apoptosis, and cellular proliferation.7
Treatments for BPH include watchful waiting for mild LUTS, pharmacologic thera-
pies (α1-adrenergic receptor antagonists and/or 5α-reductase inhibitors) for moderate 
to severe LUTS, and surgery for severe LUTS.1
Widespread in the lower urinary tract are α1-adrenergic receptors (AR). However, 
three α1-AR subtypes (α1A, α1B, and α1D) are described in human tissues,8 and α1A-AR 
is the main regulator of smooth muscle tone in the bladder neck, prostate, and prostatic 
urethra. Approximately 75% of α1-AR in the prostate belong to the α1A subtype.9,10 
Therefore, antagonism of this receptor can lead to an improvement in urinary symptoms Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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via relaxation of the lower urinary tract. Moreover, the relief 
of LUTS mediated by α-blockers is mainly explained by 
antagonism of the α1A subtype.11–13
The α1B subtype is widely found in vascular smooth 
muscle, thus blocking these proteins and causing orthostatic 
hypotension.14 The α1D subtype is predominant and functional 
in human epicardial coronary arteries, and its inhibition might 
mediate coronary vasodilation. To reduce this cardiovascular 
side effect, α1-AR inhibitors with higher selectivity for the 
α1A subtype have been developed.15 The α1A-AR inhibitor, 
silodosin (KMD-3213; Recordati Spa, Milano, Italy), was 
approved by the US Food and Drug Administration (FDA) 
for the treatment of BPH in October 2008.16
This paper reviews the literature concerning selectivity, 
mechanism of action, pharmacokinetics, recommended dos-
age, clinical efficacy, pharmacologic interactions, and side 
effects of silodosin for the treatment of BPH.
Methods
We searched Medline for peer-reviewed articles in the Eng-
lish language supporting the role for silodosin in LUTS. 
The available clinical studies are presented and discussed. 
The search terms used were “silodosin”, “α1A-blocker”, 
“lower urinary tract symptoms”, “benign prostatic hyper-
trophy”, and “uroselectivity”. The selection of papers was 
based on relevance.
Selectivity for α1A adrenoceptors
Prostate contraction is known to be the main contributor to 
LUTS in BPH, and is predominantly mediated by α1A-AR 
(Table 1).17,18 In contrast, all α1-AR (α1A, α1B, α1D) are impli-
cated in blood vessel contraction.19 Consequently, a highly 
selective α1A-AR drug can lead to better treatment and fewer 
cardiovascular side effects than a nonselective drug.20
The quinazoline α-AR blockers (alfuzosin, doxazosin, 
and terazosin) are nonselective drugs with similar affinity 
for all α1-AR, whereas tamsulosin preferentially blocks α1A 
and α1D-AR, with a 10-fold greater affinity than for α1B-AR. 
In contrast, silodosin is highly selective for α1A-AR, with a 
162-fold greater affinity than α1B-AR and about a 50-fold 
greater affinity than for α1D-AR (Table 2).21,22
The weak cardiovascular effects of silodosin have been 
demonstrated in many in vivo models. One showed better 
uroselectivity with silodosin compared with tamsulosin 
and prazosin in decerebrate dogs. Moreover, this study also 
showed that the dose required to reduce blood pressure 
by 20% was about eight fold greater with silodosin than 
tamsulosin, and about four fold greater than prazosin after 
intravenous injection (Table 3).23 In another study in dogs, 
silodosin did not affect blood pressure, heart rate, or electro-
cardiographic findings at therapeutic doses.24
Mechanism of action
The α1-ARs belong to the family of G protein-coupled 
  receptors. Binding of norepinephrine and epinephrine induces 
phospholipase C activation, leading to generation of second 
messengers, including inositol triphosphate and diacylglyc-
erol. Finally, these induce an increase in intracellular calcium 
levels and smooth muscle contraction.25 Consequently, 
blockage of α1A-AR induces prostatic and urethral smooth 
muscle   relaxation, and may improve voiding symptoms. 
However, silodosin also seems to target afferent nerves in 
the bladder, and thereby acts on bladder overactivity and 
storage symptoms.26
Pharmacokinetics and 
recommended dosage
The silodosin dose recommended by the FDA is 8 mg orally 
once a day. The drug is absorbed from the gut, and its phar-
macokinetic parameters, ie, peak plasma concentration (Cmax) 
and area under the plasma concentration versus time curve 
(AUC) increase linearly with dose.16,27
The bioavailability of silodosin is nearly 32%, with a 
distribution volume of 49.5 L, and the drug is 97% bound 
to plasma proteins.28 Time to peak concentration of silodosin 
occurs at approximately 2.6 hours after drug intake.16
It has been shown that food is involved in the pharmacoki-
netic pathway of the drug. Thus, AUC and Cmax decrease by 
4% to 49% and by 18% to 43%, respectively, with a moder-
ate calorie/fat meal. Moreover, food intake delays time to 
Cmax by about one hour. Therefore, the FDA recommends 
drug intake with meals, ideally in the morning to avoid 
the potential side effects associated with high plasma drug 
concentrations.16,27–29
Silodosin undergoes extensive metabolism involving 
glucuronidation, alcohol aldehyde dehydrogenase, and 
Table 1 α1A-adrenoreceptor selectivity of current blockers used to treat lower urinary tract symptoms18
Alfuzosin Doxazosin Silodosin Tamsulosin Terazosin
α1-adrenoreceptor  
selectivity
Nonsubtype-selective Nonsubtype-selective α1A . α1D . α1B α1A = α1D . α1B Nonsubtype-selectiveDrug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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oxidative pathways involving cytochrome P450 (CYP)3A4. 
The main metabolite in plasma is KMD-3213G. This 
metabolite is generated via the glucuronidation pathway. This 
glucuronide conjugate has been found to have a half-life of 
about 24 hours as compared with 13.3 hours for silodosin 
and an AUC three- or four fold higher than for the parent 
compound. Therefore, silodosin and its active metabolite 
have an extended half-life that makes once-daily dosing 
possible.28–30 Silodosin is excreted in the urine (33.5%) and 
feces (54.9%).16
Because the prevalence of BPH increases steeply 
with age, the pharmacokinetics of silodosin have been 
studied in elderly men (mean age 69 years) compared 
with young men (mean age 24 years).16 Both populations 
had kidney function within normally accepted limits for 
age.16 The AUC and elimination half-life of silodosin in 
elderly patients were about 15% and about 20% higher, 
respectively, than values in younger subjects. Moreover, 
no difference in silodosin Cmax was observed between the 
two groups,16 showing that the pharmacokinetic profile of 
silodosin does not change in elderly patients as compared 
with younger patients. Therefore, the standard silodosin 
dose of 8 mg once daily can be used in elderly patients 
without any titration.
A study was conducted in six patients with moderate renal 
impairment (creatinine clearance 30–50 mL/min) and seven 
patients with normal renal function. The results showed that 
the AUC, Cmax, and elimination half-life of silodosin were 
3.2-, 3.1-, and 2.0-fold greater in patients with moderate renal 
impairment than in controls. Therefore, a starting dose of 
one 4 mg capsule daily is required in patients with a creati-
nine clearance of 30–50 mL/min and   uptitration is needed 
after one week. When creatinine   clearance is .50 mL/min, 
no adjustment is needed. Silodosin use is contraindi-
cated in patients with severe renal impairment (creatinine 
clearance ,30 mL/min).16,28
With regard to hepatic impairment, a study comparing 
nine patients with moderate hepatic impairment (Child–Pugh 
score 7–9) and nine subjects with normal hepatic function 
showed no difference in the pharmacokinetic profile of silo-
dosin.16 The FDA recommendations are that no dose adjust-
ment is necessary in mild-to-moderate hepatic impairment 
(Child–Pugh score 5–9) and that silodosin is contraindicated 
in severe impairment (Child–Pugh score .10).16,28
Clinical efficacy
We reviewed the clinical efficacy of silodosin for the treat-
ment of LUTS/BPH using five clinical studies conducted 
in Japan and the US. The Japanese research was done by 
Kawabe et al,31 and comprised a 12-week, multicenter 
(n = 88) randomized, double-blind, placebo-controlled trial. 
In total, 457 patients were enrolled, and after randomization 
received silodosin 8 mg/day (n = 176), tamsulosin 0.2 mg/ 
day (n = 192), or placebo (n = 89). It must be mentioned that 
tamsulosin was used at half and even quarter of the dosage 
(0.4 mg once or twice per day) recommended by American 
Urological Association guidelines for the management 
of BPH.32
The main inclusion criteria were men aged $50 years 
with an International Prostate Symptom Score (IPSS) 
.8, quality of life (QoL) score .3, prostate volume 
.20 mL, maximum urinary flow rate (Qmax) ,15 mL/sec, 
voided volume . 100 mL, and postvoid residual urine 
volume , 100 mL.31 The IPSS is scored from 0 to 35 
(0–7 = mild, 8–19 =   moderate, 20–35 = severe) and QoL is 
scored from 0 (delighted) to 6 (terrible).
The primary endpoint of the trial was the total IPSS 
change from baseline, and secondary endpoints were 
change in Qmax, QoL score, and IPSS voiding and storage 
scores.31 Mean change (standard deviation) in total IPSS 
Table 2 Dissociation constant (Ki) and selectivity of silodosin and tamsulosin21
Ki (nM) AR subtype selectivity 
ratio
α1A-AR  α1B-AR α1D-AR α1A/α1B α1A/α1D
Silodosin 0.036 (0.010)  21 (5) 2.0 (0.4) 583  56
Tamsulosin 0.019 (0.002)  0.29 (0.02) 0.063 (0.011) 15 3
Abbreviations: AR, α-adrenoreceptor. 
Table 3 Uroselectivity of α1-blockers in decerebrate dogs23
Intravenous  
injection
Urethral  
pressure  
(ID50, μg/kg)
Blood  
pressure  
(ED20, μg/kg)
Uroselectivity   
(BP/UP)
Silodosin 3.15 8.03 2.55
Tamsulosin 1.73 0.59 0.35
Prazosin 11.8 2.46 0.21
Abbreviations: iD50, dose required to inhibit increase in intraurethral pressure 
by 50%; eD20, dose required to reduce blood pressure by 20%; BP, blood pressure; 
UP, urethral pressure.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Table 4 Results of pivotal Phase iii clinical trials
Study Patients (n) IPSS, mean (SD) Qmax, mean (SD), mL/sec
Baseline Change Baseline Change
Kawabe et al31
  Silodosin 8 mg/day 175 17.1 (5.7) -8.3 (6.4)
*
9.88 (2.75) 1.70 (3.31)
  Tamsulosin 0.2 mg/day 192 17.0 (5.7) -6.8 (5.7) 9.41 (2.81) 2.60 (3.98)
  Placebo 89 17.1 (6.1) -5.3 (6.7) 10.18 (2.72) 0.26 (2.21)
Marks et al33 (Pooled US studies)
  Silodosin 8 mg/day 466 21.3 (5.1) -6.4 (6.63)
*
8.7 (2.60) 2.6 (4.43)
*   Placebo 457 21.3 (4.9) -3.5 (5.84) 8.9 (2.80) 1.5 (4.36)
Marks et al34 (Open-label study) *
  De novo treatment 347 17.8 (6.9) -4.5 (6.7) NS NS
  Continuing treatment 314 14.5 (7.1) -1.6 (6.0) NS NS
*
Study Patients (n) IPSS voiding symptoms,  
mean (SD)
IPSS storage symptoms  
mean (SD)
Baseline Change Baseline Change
Kawabe et al31
  Silodosin 8 mg/day 175 10.8 (4.1) -5.8 (4.6)
* *
6.4 (3.0) -2.5 (2.9)
*   Tamsulosin 0.2 mg/day 192 10.8 (4.2) -4.8 (4.1) 6.2 (2.9) -2.1 (2.6)
  Placebo 89 10.9 (4.4) -3.8 (4.8) 6.3 (2.8) -1.5 (2.6)
Marks et al33 (Pooled US studies)
  Silodosin 8 mg/day 466 12 (3.6) -4.0 (4.31)
*
9.3 (2.6) -2.3 (2.93)
*   Placebo 457 12 (3.5) -2.1 (3.76) 9.3 (2.5) -1.4 (2.99)
Marks et al34 (Open-label study) * *
  De novo treatment 347 9.9 (4.5) 2.8 (4.2) 7.9 (3.2) -1.7 (3.2)
  Continuing treatment 314 7.6 (4.5) -1.0 (3.9) 6.9 (3.3) -0.6 (2.8)
  * *
Note: *P , 0.07.
Abbreviations: NS, not studied; SD, standard deviation; iPSS, international Prostate Symptom Score; Qmax, maximum urinary flow rate.
from baseline was -8.3 (6.4), -6.8 (5.7), and -5.3 (6.7) in 
the silodosin, tamsulosin, and placebo groups, respectively 
(see Table 4). For QoL score, the change from baseline 
was -1.7 (1.4), -1.4 (1.3), and -1.1 (1.2) in the silodosin, 
tamsulosin, and placebo groups, respectively. Therefore, 
silodosin was significantly better than placebo in terms of 
IPSS and QoL scores (P , 0.001 and P = 0.002, respec-
tively). The silodosin IPSS improvement effect (compared 
with placebo) became apparent at week 1 and was sus-
tained throughout the 12-week study period. At week 2, 
silodosin was significantly better than tamsulosin in IPSS 
improvement (P = 0.011) but this effect was not sustained 
throughout the trial. Thus, as compared with tamsulosin, 
silodosin showed no significant difference concerning IPSS 
and QoL scores. All three groups showed improvement 
in Qmax, with a change from baseline of 2.24 (3.96), 2.95 
(4.64), and 2.42 (5.50) mL/sec in the silodosin, tamsulosin, 
and placebo groups, respectively. However, there was no 
significant difference between the groups.31 IPSS voiding 
symptoms were significantly improved in the silodosin 
group compared with the other two groups (P , 0.001 
versus placebo, P = 0.023 versus tamsulosin). For storage 
symptoms, improvement by silodosin was statistically 
significant compared with that on placebo (P , 0.006), 
but no significant difference was recorded for tamsulosin 
(P = 0.106).
Two pivotal Phase III US trials of 12 weeks’ duration 
are presented in the silodosin prescribing information, 
and have been published in a pooled analysis.16,33 This 
pooled analysis was followed by a nine-month open-
label extension study.34 Both studies randomized 457 and 
466 patients, respectively, to receive placebo or silodosin 
8 mg/day.33 The main inclusion criteria were men aged 
$50 years with an IPSS . 13, Qmax 4–15 mL/sec, mini-
mum voided volume $125 mL, and postvoid residual urine 
volume ,250 mL.33
The primary endpoint of the trial was the total IPSS 
change from baseline and secondary endpoints were change 
in Qmax and in IPSS voiding and storage scores.33 After 
3–4 days of treatment, the improvement in total IPSS from 
baseline was significantly greater (P , 0.001) in the pooled 
silodosin group (-4.2 [5.26]) than in the pooled placebo Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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group (-2.3 [4.37]). This significant decrease was sustained 
throughout the 12-week study (-6.4 [6.63] versus -3.5 [5.84], 
P , 0.001). Moreover, a significant increase in Qmax from 
baseline occurred 2–6 hours after the first dose (P , 0.001) 
in the pooled silodosin group (2.8 [3.44] mL/sec) compared 
with the pooled placebo group (1.5 [3.76] mL/sec). Differ-
ences remained significant through to week 12 (2.6 [4.43] 
versus 1.5 [4.36] mL/sec, P , 0.001). Irritative/storage 
symptoms decreased significantly in the pooled silodosin 
group from the first postbaseline assessment throughout the 
study (P , 0.001 for each subscore compared with the pooled 
placebo group, Table 4).33
In total, 661 patients from the pooled study were invited 
to participate in an open-label nine-month extension study 
to evaluate the long-term safety and efficacy of chronic 
dosing with silodosin (Table 4).34 Of the patients enrolled in 
this study, 347 received silodosin for the first time (de novo 
treatment group) and 314 subjects continued treatment with 
silodosin (continuing treatment group).33 The continuing 
treatment group had lower baseline IPSS values than the de 
novo treatment group at the beginning of the nine-month 
study. At the end of the study, the IPSS irritative/storage 
subscores showed a significant decrease from baseline in 
both groups (P , 0.01). The total IPSS change from base-
line was -4.5 (6.7) for de novo treatment and -1.6 (6.0) for 
continuing treatment through to week 40 (P , 0.01 for both 
values compared with baseline).34
Pharmacologic interactions
Because silodosin is metabolized via the CYP3A4 pathway, 
it is contraindicated in patients taking strong CYP3A4 inhibi-
tors, including clarithromycin, itraconazole, ketoconazole, 
and ritonavir. These drugs increase the serum concentration 
of silodosin and the potential risk of side effects by slowing 
or inhibiting the silodosin metabolism. It has been shown 
that silodosin 8 mg coadministered with ketoconazole 
400 mg increases the Cmax and AUC of silodosin by 3.8- and 
3.2-fold, respectively.16 Caution is needed when silodosin 
is used concurrently with moderate CYP3A4 inhibitors, 
although potential interactions have not been studied. 
Silodosin can be coadministered with phosphodiesterase 
type 5   inhibitors. Indeed, a placebo-controlled, open-label 
crossover study showed minimal reductions in systolic and/
or diastolic blood pressure after coadministration of silodosin 
with   phosphodiesterase type 5 inhibitors (sildenafil 100 mg 
or tadalafil 20 mg).35
With regard to interaction with antihypertensive agents, 
there are no studies as yet that have assessed this problem 
rigorously. However, it is important to note that about 
one-third of patients enrolled in the US studies were taking 
antihypertensive agents.33 Analysis of the results showed that 
patient taking antihypertensive agents and silodosin together 
had more episodes of dizziness than normotensive patients 
taking silodosin alone (4.6% versus 3.8%, respectively), 
as well as a greater frequency of orthostatic hypotension 
(3.4% versus 3.2%).33 Therefore, careful use and attentive 
monitoring should be performed, and further clinical studies 
are mandatory.
Undesirable effects
Despite its high uroselectivity, silodosin is associated with 
side effects (summarized in Table 5). In the Japanese and 
US studies, the most commonly reported adverse reaction 
was retrograde ejaculation (22.3% and 28.1%, respectively, 
compared with 1.6% with tamsulosin and 0%–0.9% with 
placebo).31,33 This adverse event was the main cause of 
treatment discontinuation of silodosin (2.8% and 2.9%, 
respectively).31,33 Retrograde ejaculation is the result of 
smooth muscle relaxation in the prostate, urethra, bladder 
neck, and vas deferens.36,37 The α1A-AR is mainly expressed 
in the bladder neck, vas deferens, and seminal vesicles.38 
Moreover, a pharmacologic study showed that the α1A-AR 
subtype mediates human vas deferens contraction.39 Thereby, 
this adverse reaction is explained by the high α1A-AR subtype 
selectivity of silodosin. The other adverse events commonly 
associated with silodosin were upper respiratory tract infec-
tion (18.9% versus 27.6% and 19.1% with tamsulosin and 
placebo, respectively), thirst (10.3% versus 3.6% and 4.5%), 
loose stools (9.1% versus 3.6% and 5.6%), urinary incon-
tinence (6.3% versus 5.7% and 0%), diarrhea (2.6%–6.9% 
versus 6.8% and 5.6%), dizziness (3.2%–5.1% versus 7.3% 
Table 5 Adverse effects of silodosin compared with tamsulosin 
and placebo
Adverse effects Silodosin  
(%)
Tamsulosin  
(%)
Placebo   
(%)
Retrograde  
ejaculation
22.3–28.1 1.6 0–0.9
Upper respiratory  
tract infection
18.9 27.6 19.1
Thirst 10.3 3.6 4.5
Loose stool 9.1 3.6 5.6
Urinary  
incontinence
6.3 5.7 0
Diarrhea 2.6–6.9 6.8 5.6
Dizziness 3.2–5.1 7.3 4.5
Orthostatic  
hypotension
2.6 – 1.5Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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and 4.5%) and orthostatic hypotension (2.6% versus1.5% 
for placebo).31,33
The open-label extension study done by Marks et al 
permitted evaluation of the long-term safety of silodosin.34 
Retrograde ejaculation occurred more often among patients 
on de novo treatment than in patients who were continuing 
treatment (31.1% versus 9.6%, respectively). Orthostatic 
hypotension occurred in the same range (2.9% versus 2.2%, 
respectively). More patients receiving de novo treatment 
(7.5%) discontinued the study because of retrograde ejacu-
lation than those continuing treatment (1.9%). During this 
extension study, no cardiac disorders and no prolongation 
of corrected QT interval were found with long-term use of 
silodosin.35
Intraoperative floppy iris syndrome (IFIS) is a complica-
tion of cataract surgery observed in patients who have been 
previously treated with α1-blockers, mainly tamsulosin. The 
clinical manifestations of IFIS are pupil constriction, flutter-
ing, and billowing of the iris stroma, with a propensity of the 
iris to prolapse during cataract surgery.40 A prospective study 
was conducted in 1968 Japanese patients receiving various 
α1-blockers, including silodosin, before cataract surgery.41 The 
overall incidence of IFIS was 1.1% and, interestingly, no IFIS 
occurred in patients receiving silodosin. However, one case of 
IFIS has been reported in a nine-month, open-label, tolerability 
study of silodosin.16 Nevertheless, patients need to inform their 
ophthalmologist about silodosin use, and it is recommended to 
stop the medication before cataract surgery is performed.
Conclusion
Alpha-blockers remain the first-line therapy for LUTS in 
BPH. Silodosin, a new α1A-blocker, has been approved by 
the FDA since October 2008 at a recommended dose of 8 mg 
orally once daily. Clinical studies have shown that this selec-
tive α1A-AR is very attractive and more effective than placebo 
for voiding and storage symptoms in LUTS arising from 
BPH. Silodosin has excellent early efficacy, and is at least 
as effective as for other α1-blockers. Silodosin distinguishes 
itself by a strong effect not only on symptoms but also on 
obstruction as measured by pressure flow studies, a finding 
perhaps explained by its strong selectivity for α1A-AR. At the 
present time, it is still unknown whether combining silodosin 
with 5α-reductase inhibitors is better than either treatment 
alone for reducing progression of the disease.
Although silodosin is very attractive, a long-term study 
comparing this drug with other α1-blockers, especially tamsu-
losin, is needed to help physicians write the right prescription 
for the treatment of BPH and LUTS in men.
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